source
- Definium's oral LSD candidate passes first Phase 3 trial in generalized anxiety disorderDefinium Therapeutics announced that its oral LSD candidate has successfully completed a Phase 3 trial in generalized anxiety disorder. The study met its primary endpoints, marking the first of tw…
- Definium's LSD-based therapy shows strong Phase 3 results in generalized anxiety disorderDefinium Therapeutics reported that its LSD-derived oral tablet, DT120, met its primary endpoint in a Phase 3 trial for generalized anxiety disorder. The study enrolled over 200 participants and co…